Increasing Survival in Stage III NSCLC: Optimizing Care and Addressing New Clinical Challenges
  • CME
  • MOC

In this CME/MOC-certified, on-demand Webcast of a CCO symposium at CHEST 2019, a multidisciplinary panel of expert faculty, including a medical oncologist, a radiation oncologist, and a pulmonologist, review and discuss the latest data on optimal integration of immune checkpoint inhibitors into the care of patients with stage III NSCLC.
Gerard A. Silvestri, MD, MS
Program Director
Kristin Higgins, MD
Mark A. Socinski, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
US Physicians: maximum of 1.0 Medical Knowledge MOC point(s)
Released: November 20, 2019 Expiration: November 19, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss the biologic rationale for using immune checkpoint inhibitors in patients with locally advanced NSCLC
  • Plan optimal, individualized therapeutic strategies, including whether to pursue resection, for patients with stage III NSCLC, considering the available clinical evidence, expert recommendations, and patient preferences
  • Identify subsets of patients with stage III NSCLC most likely to benefit from durvalumab consolidation after definitive platinum-based chemotherapy and concurrent radiation therapy
  • Identify subsets of patients with stage III NSCLC most likely to benefit from pembrolizumab
  • Describe ways that the use of immunotherapy in earlier stages of disease may require a different understanding of risk/benefit and applicable subsets of patients
  • Manage immune-mediated adverse events with the use of automated decision support resources and guidelines

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Gerard A. Silvestri, MD, MS

Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Medical University of South Carolina
Charleston, South Carolina

Gerard A. Silvestri, MD, MS, has disclosed that he has received consulting fees from AstraZeneca.

Faculty

Kristin Higgins, MD

Medical Director
Associate Professor

Department of Radiation Oncology
Emory University
Atlanta, Georgia

Kristin Higgins, MD, has disclosed that she has received consulting fees from AstraZeneca and Varian and funds for research support from Reflexion.
Mark A. Socinski, MD

Executive Medical Director
Member,
Thoracic Oncology Program
AdventHealth Cancer Institute
Orlando, Florida

Mark A. Socinski, MD, has disclosed that he has received funds for research support from AstraZeneca, Genentech, Novartis, and Spectrum; consulting fees from Genentech, Lilly, and Novartis; and fees for non-CME/CE services from AstraZeneca, Bayer, and Genentech.

Staff

Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has reported that his spouse/partner has ownership interest (stock) in AstraZeneca.
Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for pulmonologists and other healthcare providers who care for patients with non–small-cell lung cancer.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of pulmonologists, oncology specialists, and other clinicians to integrate immune checkpoint inhibitors into treatment of their patients with stage III non-small-cell lung cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

If you are interested in having us report ABIM MOC, please ensure the following information is provided within your CCO Member Profile:

Name - as registered with ABIM
Date of Birth (Month/Day)
Your ABIM ID number

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 20, 2019, through November 19, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

CCO faculty H. Jack West, MD, discusses shared decision-making in this brief video for patients with advanced NSCLC who are candidates for immunotherapy

H. Jack West, MD Released: January 30, 2020

Download this slideset for expert perspectives on the optimal use of immunotherapy for advanced NSCLC, including thoughts on involving your patients in treatment decisions.

H. Jack West, MD Helena A. Yu, MD Released: January 28, 2020

Matthew Gubens, MD, MS, provides expert insight on frontline combination regimens using immunotherapy in advanced NSCLC.

Matthew Gubens, MD, MS Released: December 30, 2019

Download this PDF resource for patients with advanced NSCLC receiving immune checkpoint inhibitor therapy, including information on what to expect and how to actively participate in their care.

Released: December 12, 2019
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?